Bicycle Therapeutics (BCYC) Change in Receivables (2018 - 2025)
Bicycle Therapeutics' (BCYC) quarterly Change in Receivables came in at $133000.0 in Q1 2025, down 99.73% on a QoQ basis from $49.9 million in Q3 2023.
Bicycle Therapeutics (BCYC) Change in Receivables (2018 - 2025) Analysis & Trends
Bicycle Therapeutics (BCYC) has 7 years of Change in Receivables data on file, last reported at $133000.0 in Q1 2025.
- Quarterly Change in Receivables changed N/A year-over-year to $133000.0 in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $170000.0 (changed N/A YoY) and the FY2023 annual result came in at -$2.5 million, down 251.25% from the prior year.
- Change in Receivables fell to $133000.0 in Q1 2025, from $49.9 million in the prior quarter.
- In the past five years, Change in Receivables ranged from a high of $49.9 million in Q3 2023 to a low of -$49.8 million in Q2 2023.
- A 4-year average of -$477363.6 and a median of -$991000.0 in 2022 frame the typical range for Change in Receivables.
- The widest YoY moves for Change in Receivables: up 614.5% in 2023, down 582.14% in 2023.
- Tracing BCYC's Change in Receivables over 4 years: stood at $1.0 million in 2021, then surged by 98.7% to $2.0 million in 2022, then jumped by 2407.59% to $49.9 million in 2023, then slumped by 99.73% to $133000.0 in 2025.
- The last three Change in Receivables figures came in at $133000.0 (Q1 2025), $49.9 million (Q3 2023), and -$49.8 million (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 140.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 838.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 117.58 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -483,662.49 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 31.60 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 37.16 Mn |
| 10 | Bicycle Therapeutics | 272.28 Mn | 272.28 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2025 | 133,000.00 |
| Mar 31, 2025 | 133,000.00 |
| Sep 30, 2023 | 49.88 Mn |
| Sep 30, 2023 | 49.88 Mn |
| Jun 30, 2023 | -49.84 Mn |
| Jun 30, 2023 | -49.84 Mn |
| Mar 31, 2023 | -2.52 Mn |
| Mar 31, 2023 | -2.52 Mn |
| Dec 31, 2022 | 1.99 Mn |
| Dec 31, 2022 | 1.99 Mn |
| Sep 30, 2022 | -9.69 Mn |
| Sep 30, 2022 | -9.69 Mn |
| Jun 30, 2022 | 10.34 Mn |
| Jun 30, 2022 | 10.34 Mn |
| Mar 31, 2022 | -991,000.00 |
| Mar 31, 2022 | -991,000.00 |
| Dec 31, 2021 | 1.00 Mn |
| Dec 31, 2021 | 1.00 Mn |
| Jun 30, 2021 | -2.02 Mn |
| Jun 30, 2021 | -2.02 Mn |